20 results
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
21 Mar 24
Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
4:02pm
in achieving our mission of expanding PEDMARQSI to patients across the globe who are at risk of suffering from cisplatin-induced ototoxicity,” said
8-K
EX-99.1
FENC
Fennec Pharmaceuticals Inc
11 Feb 20
PEDMARKTM1 is Being Developed for Prevention of Cisplatin-Induced Hearing Loss in Children
2:17pm
are the culmination of many years of hard work, bringing us one step closer to achieving our mission,” said Rosty Raykov, chief executive officer of Fennec
424B3
49krjtv6ych2yp8uo0w
21 Apr 14
Prospectus supplement
12:00am
424B3
rmu2xbtd0wjifht
4 Apr 13
Prospectus supplement
12:00am
POS AM
g22qb2ca qv0x
1 Apr 13
Prospectus update (post-effective amendment)
12:00am
424B3
car3kcoadfwy9p84
26 Aug 11
Prospectus supplement
12:00am
8-K
j5u 1pfkjmf
26 Aug 11
Adherex Announces Completion of Reverse Stock Split and Continuance to British Columbia
12:00am
- Prev
- 1
- Next